Someone else more qualified to dive into the science will likely...

Someone else more qualified to dive into the science will likely chime in, but my understanding from listening to YF and co is that CF33 is a virus that only attacks cancer cells = good.

The body likes good = it doesn't attack CF33 as its a friendly.

Its with this line of thinking that holds exceptional potential value, in theory a patient could be dosed CF33 via IV (in a large enough dosage) that it travels around the body and seeks out the cancerous tumours, diagnosed and even undiagnosed, and goes to work. Its then also been said to have the potential of remaining in the body for some time, in essence protecting the patient from any new cancers that could develop.

That's my very basic understanding and laymen's terms of the potential of what Yuman has created here. #yuman4nobel
So to see it working so early at such small dosage in a Ph1 is extremely promising for both patients and shareholders. And shareholders who statistically might find themselves patients at some point in the future.

GLA